)
Visual
test
Tonix Pharmaceuticals
Tonix Pharmaceuticals (TNXP) investor relations material
Tonix Pharmaceuticals Stifel 2025 Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Stifel 2025 Healthcare Conference summary13 Nov, 2025
Financial and operational highlights
Ended September with $190 million in cash, no debt, and a simple cap table; cash runway extends into Q1 2027, fully funding the product launch.
Commercial launch of newly approved fibromyalgia treatment Tonmya set for before end of November, with experienced sales team and omnichannel prescriber engagement.
Tonmya added to existing wholesaler and specialty pharmacy contracts; robust patient access and support services planned at launch.
25,000 healthcare providers write 70% of fibromyalgia prescriptions; 90 sales reps to target 70% of these prescribers.
Recent acquisition of two acute headache products provided commercial foundation for Tonmya launch.
Product and market insights
Tonmya is the first new fibromyalgia drug approved in over 15 years, with unique sublingual cyclobenzaprine formulation and patent exclusivity until 2034.
Addresses significant unmet need: 10 million Americans affected, only 3 million diagnosed and treated; high dissatisfaction with current therapies and high off-label opioid use.
Tonmya’s efficacy demonstrated by higher responder rates in clinical trials and favorable tolerability profile, with minimal withdrawal due to side effects.
Commercial strategy includes proportional pricing for different patient groups and early prescriber outreach.
Pipeline and R&D updates
Multiple pipeline programs advancing: TNX-102 SL for acute stress disorder (enrolling), major depressive disorder (study starts next summer), and prior PTSD studies provided strong mechanistic rationale.
Anti-CD40 ligand antibody completed phase 1, phase 2 kidney transplant study to start in first half of next year in partnership with Mass General Hospital.
TNX-4800, a long-acting antibody for Lyme disease, licensed from University of Massachusetts, phase 2 ready, offers immediate and season-long protection.
Intranasal oxytocin/magnesium for Prader-Willi syndrome to enter pivotal study in second half of next year, supported by compelling animal data.
What is the strategy to convert off-label opiate use?
How does anti-CD40 ligand avoid prior drug risks?
Explain TNX-102 SL's ASD development rationale
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- MATAS
Record Q3 for Matas, but KICKS declined as consumers traded down; guidance maintained. - SVIK
Profitability and cash flow surged in 2025, led by fuel and waste tech growth and no dividend proposed. - NOD
Q4 2025 delivered strong revenue and margin growth, with a positive outlook for Q1 2026. - BUFAB
Record-high margins and strong Q4 results support optimism for growth in 2026. - SLP
Record 2025 growth: rental income +43%, profit +46%, SEK 800m share issue, 95% sustainable financing. - RBX
Order book up 8% to R30.44bn, but profit and EPS declined; outlook remains positive. - AFRY
Q4 margin and utilization gains, strong backlog, and stable dividend despite market headwinds. - GEM
Losses narrowed, costs cut, and Bitcoin strategy adopted as political delays continue. - BTE
Post-Eagle Ford sale, focus shifts to Canadian growth, capital returns, and operational efficiency. - CPG
Q1 organic revenue up 7.3%, strong new business, and 2026 profit growth guidance reaffirmed.
Next Tonix Pharmaceuticals earnings date
Q4 202513 Mar, 2026
Tonix Pharmaceuticals
Next Tonix Pharmaceuticals earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing therapies for central nervous system disorders, rare diseases, and infectious diseases. The company’s pipeline includes treatments for conditions such as post-traumatic stress disorder (PTSD), fibromyalgia, and long COVID. Tonix Pharmaceuticals also explores vaccine and antiviral drug candidates for infectious disease prevention and treatment. The company is headquartered in Chatham, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage